Lilly’s triple-G retatrutide ‘best-in-class’ as BLA filing nears
· karen carey
AI Briefing
- • Lilly's retatrutide scores high in phase III trials for type 2 diabetes and cardiovascular complications.
- • Retatrutide shows potential to surpass top marketed drugs in the obesity treatment space.
- • BLA filing for retatrutide nears, following successful trial results.
Context
Eli Lilly and Co. has achieved high marks in two phase III obesity trials for its triple-G candidate retatrutide. The trials involved patients with serious type 2 diabetes and cardiovascular complications.
Retatrutide is expected to surpass the top two marketed drugs in its space, with a BLA filing nearing.
Advertisement